Engaging novel cell types, protein targets and efficacy biomarkers in the treatment of diabetic nephropathy

Ryan M Fryer; Carine M Boustany-Kari; Scott M MacDonnell

doi:10.3389/fphar.2014.00185

Engaging novel cell types, protein targets and efficacy biomarkers in the treatment of diabetic nephropathy

Front Pharmacol. 2014 Aug 7:5:185. doi: 10.3389/fphar.2014.00185. eCollection 2014.

Authors

Ryan M Fryer¹, Carine M Boustany-Kari¹, Scott M MacDonnell¹

Affiliation

¹ Boehringer Ingelheim Pharmaceuticals, Inc., Cardiometabolic Diseases Research Ridgefield, CT, USA.

No abstract available

Keywords: ERK5; MEK5; N-acetyl-seryl-aspartyl-lysyl-proline; PF-03882845; angiopoietin-like protein 4; chronic kidney disease; diabetic nephropathy; mineralocorticoid antagonist.